age1 funds breakthrough longevity companies addressing the core challenges of the field. We help contrarian founders build generational biotech companies. Our expertise is at the earliest stage possible. We are a next-generation fund accelerating the longevity paradigm shift. We value pragmatism, rigor, and optimism. Launched from The Longevity Fund, we’ve backed some of the first longevity biotech companies to IPO and achieve clinical translation. Our vision is to make aging and age-related diseases optional for all.
| Website | https://age1.com/ |
| Employees | 8 (6 on RocketReach) |
| Founded | 2023 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+10 more
(view full list)
|
| Industry | Venture Capital and Private Equity Principals, Biotechnology, Science and Engineering, Business Development, Financial Services |
| Keywords | Longevity, Biotech, Venture Capital, Life Sciences, Aging Research, Geroscience, Health Tech, Regenerative Medicine, Therapeutics, Biotechnology, Pharmaceutical, Startups, Early Stage Investing, Seed Funding, Breakthrough Technologies, Innovative Therapies, Clinical Development, Drug Discovery, Next Generation Therapeutics |
| Competitors | 3M, Align Technology, Straumann, SmileDirectClub, ClearCorrect, byte®, Discus Dental, Invisalign Orthodontist US, ALIGNERCO, SnapCorrect +23 more (view full list) |
Looking for a particular AGE1 employee's phone or email?
Alex Colville is the General Partner of AGE1.
6 people are employed at AGE1.
AGE1 is based in San Francisco, California.